Organ-on-a-Chip Resources

The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, what can be embraced in its place?

What is the FDA Modernization Act 2.0, and what does it mean?

Normalization of organ-on-a-Chip samples for mass spectrometry based proteomics and metabolomics via Dansylation-based assay

Gallagher et al., 2022

This study shows the importance of normalization for paired MS-based multi-omics-OOC studies to accurately investigate highly toxic hazards and their effects on the human liver. Using VX, a highly toxic chemical compound, the study identifies VX-specific toxic effects on 3D liver tissues as well as specific hepatic cellular biomarkers and pathways affected by the toxic agent.

The Human Touch: Primary Human Microphysiological Systems for Testing HSD17B13 Inhibitors

Webinar Series 5 Episode 4

In this webinar, we highlight how the liver-on-a-chip system can be used to assess the impact of HSD17B13 inhibitors on fibrosis, human metabolism and lipid droplets.

ADME Studies: Determining Promising Drug Compounds

Dr Abbas discusses factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.

This article is taken from PharmTech, November 2022.

The Dash for NASH: How To Succeed in NASH Therapeutic Development

Webinar Series 5 Episode 3

Find out how to: rapidly adopt an organ-on-a-chip (OOC) approach to NASH research, generate clinically translatable data from an industry-proven in vitro NASH model, and how OOC can help you unlock NASH disease mechanisms, and confirm drug efficacy and safety.

How to Keep Breathing – The Future of Inhaled Medication Testing

Dr Emily Richardson discusses the current challenges faced to bring inhaled therapeutics to the market and the potential of Organ-on-a-Chip to increase positive outcome by improving ADME drug testing.

This article is taken from International Biopharmaceutical Industry, Summer 2022.

PhysioMimix Multi-organ System Animation

An introduction to the CN Bio PhysioMimix Multi-organ System. This animation demonstrates how our microphysiological system works, how to create a Gut/Liver-on-a-chip model and an example of its use.

Evaluation of in vitro human alveolar and bronchial microphysiological systems to predict the permeability and absorption of inhaled pulmonary medications

The lung is the most vulnerable internal organ to infection and injury due to its constant exposure to inhaled particles and pathogens from the environment. Coinciding with this, respiratory diseases are a leading cause of death and disability.

Human liver microphysiological system for predicting the drug-induced liver toxicity of differing drug modalities

Novac et al

The liver is one of the organs most susceptible to drug toxicity and drug-induced liver injury (DILI). With more than 750 FDA-approved drugs known to have a degree of DILI risk, better preclinical models are required to de-risk new therapeutics earlier in the drug development process.​ We assess whether a Liver MPS model could be used to understand the detailed mechanistic aspects of liver toxicity.

Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury

Kostrzewski et al

As a result of the increased prevalence of diabetes, obesity, and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries. Using better in vitro models to fast-track therapeutic development but also accurately assess DILI risk in NASH patients ahead of the clinic is critical. Here, we show the potential of an in vitro 3D NASH model to accurately identify any DILI-associated risks.

Application of a gut–liver-on-a-chip device and mechanistic modeling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil

Milani et al., 2022

This study shows how an in vitro gut-liver multi-organ model can quantitatively recapitulate the in vivo metabolism of a drug. By combining Organ-on-a-chip with in silico modeling, the study also demonstrates the potential of multi-organ models for quantitative estimation of PK parameters of a drug and its metabolites.

Turning to Organ-on-a-Chip Studies for the Future of Drug Discovery

What are the biggest challenges currently in drug discovery? How is Organ-on-a-chip (OOC) accelerating the drug discovery process? What advantages does OOC have over animal and 2D in vitro models? What could this mean for the future of drug development? Read now to hear our VP answer all these questions.

This article is taken from News Medical, August 2022.